The diagnosis of neuroblastoma was based on conclusive clinical, laboratory and imaging findings and was always confirmed by histology and/or cytology. The primary tumour was evaluated by computed tomography scan or magnetic resonance imaging (MRI) and/or ultrasonography and iodine 123 or 131 metaiodobenzylguanidine (MIBG) scintigraphy (McEwan et al, 1985) . The complete metastatic work-up included a skeletal study by MIBG (or a Technetium 99m scan in the absence of MIBG-uptake at the site of the primary tumour), a complete examination of the skeleton by X-rays and extensive bone-marrow staging (according to INSS criteria). When MIBG-uptake was detected in metastases, several views were obtained to confirm that uptake was exclusively localized in the skeleton and not in soft tissues. In addition, the films and scans were centrally reviewed if MIBG scan showed uptake in one or several skeletal sites. Urinary vanillylmandelic (VMA) and homovanillic (HVA) acid levels and dopamine excretion according to creatinine concentration (Bertani-Dziedzic et al, 1990) were measured, as were serum neuron-specific enolase (NSE) (Zeltza et al, 1986) , ferritin (Hahn et al, 1980) , and lactate dehydrogenase (LDH) levels.
Analysis of the MYCN oncogene was planned for all tumours. Results were considered reliable only if tumour material exhibited over 10% of neuroblasts. MYCN genomic content was determined by Southern or slot blot using MYCN second exon probes. MYCN amplification (MNA) was defined as ≥ 10 copies per haploid genome. Other biological investigations such as evaluation of the DNA index (Look et al, 1984) or a search for deletion of the short arm of chromosome 1 (Caron, 1993) were optional.
Labreveux de Cervens et al (1994) defined three groups of infants with stage 4 neuroblastoma. These groups appeared different in terms of median age, response to chemotherapy and long-term survival. In our study, the 51 infants with stage 4 disease were then divided into these three groups:
Group I comprised 21 infants whose bone lesions were detected by X-ray. None of these patients had a normal skeletal MIBG scan (or Tc 99m scan); they all exhibited skeletal uptake.
Group II comprised 22 infants with metastatic disease but with no detectable bone lesion neither by MIBG nor by X-ray. The primary tumour in this group was considered unresectable and associated with metastases, especially in the liver, skin, or slight bonemarrow involvement. Tumours were defined as unresectable when they traversed and invaded the midline structures, usually those encasing large vessels, or when their size, structure, or location prohibited surgery without a high risk of rupture or major surgical complications. The latter included some large thoracic tumours that compressed the upper respiratory tract without necessarily crossing the midline extensively. All dumbell tumours, with or without neurologic impairment, were deemed unresectable .
Group III consisted of eight infants, in which bone lesions were not detected by X-ray but the MIBG scan showed uptake in one or several skeletal sites. This group includes patients with MIBG features consistent with cortical bone disease and those with features consistent with bone marrow involvement.
Thus, 51 evaluable infants with stage 4 disease entered the study, 21 had radiologically detectable bone lesions and 30 had not (22 unresectable primary tumours and eight only exhibiting MIBG skeletal uptake).
Therapeutic protocol

Chemotherapy
Group I Chemotherapy consisted of four courses of cyclophosphamide-doxorubicin-vincristine CAdO (Coze et al, 1997), followed by surgery if complete remission was obtained at all metastatic sites and high-dose chemotherapy (HDC) with stem cell transplantation (SCT) in case of MNA. In the event of no response or progressive disease after the first two courses of CAdO, treatment was switched for etoposide and platinum compounds, as in the case of patients with stage 4 neuroblastoma over 1 year-of-age (Coze et al, 1997), followed by surgery and HDC with SCT if complete remission (CR) or partial remission (PR) was obtained.
Group II These patients received the same treatment as that administered for localized unresectable neuroblastoma. Chemotherapy consisted of two courses of carboplatin and etoposide (Frappaz et al, 1992) , followed by two courses of CAdO. All patients received four courses of chemotherapy, and radical surgery was then attempted. After surgery, chemotherapy was indicated for residual disease and/or lymph-node involvement (one course of each combination).
Group III Treatment of these patients was left to the discretion of the physician. Patients were treated either like stage 4-s (Michon et al, 1993) or like stage 4 without HDC if MYCN was not amplified (MNN). In keeping with the NBL 90 protocol, stage 4-s lesions were treated according to the evolutionary course of the disease. Initial treatment included six courses of cyclophosphamide and vincristine (CO), followed by surgery. If no response was obtained or disease progressed after CO, second-line therapy using irradiation or chemotherapy was given, followed by surgical excision of the primary tumour.
According to the NBL90 protocol, all patients with metastatic neuroblastoma (groups I, II and III) and MNA received high-dose chemotherapy followed by SCT.
Radiotherapy
After November 1992, because of a high incidence of local relapses, locoregional irradiation was recommended for infants whose tumour exhibited MNA, regardless of age or the quality of the surgical excision. A total dose of 25 Gy was delivered in daily fractions of 1.5-1.8 Gy each.
Evaluation of reponse to therapy
Response to therapy was assessed according to INSS criteria (Brodeur et al, 1971) . Response was defined as follows: complete remission (CR) = no detectable disease; very good partial remission (VGPR) = only a small local tumour residue (< 10% of the initial size) but no detectable disease at any site of metastasis; partial remission (PR) ≥ 50% reduction of all measurable and evaluable disease. All other situations were considered as failures (mixed response (MR), no response (NR) and progressive disease (PD)). Tumour response was evaluated during and at the end of induction therapy, 1 month after surgery and 6-8 weeks following HDC, and at least every 3 months thereafter.
Statistical analysis
A comparison of infants whose tumours were MYCN amplified (MNA) and those whose tumours were not MYCN amplified (MNN) was performed for each variable with the χ 2 test corrected for heterogeneity or Fisher's exact test (Peto et al, 1977) . The probabilities of survival were calculated from the time-ofdiagnosis to relapse, or death, or last follow-up, according to the Kaplan-Meir product-limit method (Fleiss, 1981) . In the eventfree-survival (EFS) analysis, disease progression or relapse, and death, whatever the reasons, were considered as events. Multivariate assessment of EFS was performed using Cox's proportional hazards model and curves were compared using the log-rank test .
RESULTS
Patient characteristics
Patient characteristics are listed in Table 1 . The median age was 7 months (range: newborn-12 months). The primary tumour was abdominal in 37 patients (73%). Ten children had a dumbbell tumour (seven thoracic, one cervical, one abdominal, and one pelvic tumour). Forty-five of 51 patients with metastatic disease had multiple sites of metastasis. The bone marrow (n = 36) and the liver (n = 25) were the most frequently involved. MYCN oncogene content was assayed in 47 tumours and found to be amplified (≥ 10 copies) in 17 (37%).
Neuroblastoma stage 4 with bone lesions (group I)
The bone metastases of the 21 patients in this group were detected by both X-ray and MIBG or Tc 99m scan. Patient characteristics are listed in Table 2 . The sex ratio was 16 males/5 females, and the median age was 9 months (range = 1-12 months). The primary tumour was abdominal in 20 patients. All these 21 patients had a single or multiple bone lesions on X-ray films. Three of them presented a single site of uptake on MIBG scan (and one or several radiologically detectable bone lesions), whereas 17 had multiple sites of osteomedullary uptake. One last patient had a negative MIBG scan even at the primary tumour site, but the Tc 99m bone scan showed a single positive lesion. MYCN oncogene content was found to be amplified (≥ 10 copies) in 13/21 (62%).
Seven of these 21 infants achieved a CR of all metastatic sites following first-line chemotherapy. Four of them were consolidated with high-dose chemotherapy (HDC) because of MYCN amplification. Of these four, two are alive in first CR with a follow-up of 69 and 9 months post-diagnosis, one died of infection 28 months after HDC, and one relapsed 7 months after HDC and died. One other patient with MNA, who was not consolidated, relapsed 2 months after surgery and died. The two patients with MNN who achieved a CR were treated with conventional chemotherapy and surgery. One of them is alive in first CR having attained a followup of 75 months, and the other died of treatment-related complication after HDC performed in second PR.
The fate of the other 14 patients was as follows: in one, disease progressed rapidly during induction and he died. One infant died of infection after two courses of CAdO. The twelve remaining infants achieved a partial response (PR) of their metastases after first-line chemotherapy (CAdO). Two of them (MNA) died of disease progression, and ten achieved a CR or VGPR on secondline therapy (etoposide/platinum). Nine of these ten were further consolidated with HDC. Four of them are alive and free of disease (> 64, 49, 22 and 12 months) (three MNN) and the other five died of disease. The remaining patient (MNN), who entered VGPR after second-line therapy, was not consolidated with HDC and is alive and free of disease (> 65 months).
Hence 8/21 patients with bone lesions are alive and free of disease, of whom three had MNA and five have MNN tumour.
Neuroblastoma stage 4 without bone lesion (group II and III)
Group II Bone metastases were not detectable either by X-ray or MIBG scan in the 22 infants in this group (Table 2 ). The sex ratio was 8 males/14 females, and the median age was 4 months (range = 0-11 months). The primary tumour was abdominal in 12 patients, thoracic in five, cervical in two, cervico-thoracic in two and pelvic in one. A dumbbell tumour was found in seven patients. MYCN oncogene content was assayed in 18/22 tumours and found to be amplified in four (22%).
Ten infants without MYCN amplification were treated according to the NBL90 protocol. All are alive in first CR with a follow-up of 5-68 months post-diagnosis. Four other infants, with an MNN tumour, were treated like stage 4-s disease (protocol violations). Only one achieved a CR and is alive and free of disease (> 25 months). Disease progressed on therapy in the other three and they entered CR after second-line therapy and are alive (> 82, 25 and 6 months). Of the four other infants with MNA tumour, two were consolidated and are alive and free of disease (> 51 and 44 months). The third was treated only with the conventional NBL90 chemotherapy and he is alive in first CR (> 53 months). The fourth patient died of a surgical complication during initial biopsy. The MYCN status was unknown (MNU) in four patients because the tumour-cell content of the sample was poor (n = 2), or because it was not analysed (n = 2). One of them died of sepsis after four courses of chemotherapy. Another, treated according to the protocol, is alive in first CR with a follow-up of 65 months. The remaining two patients were treated like stage 4-s disease and are alive and free of disease (> 69 and 33 months).
In summary, in this group, 20/22 infants are alive in CR or PR, of whom 14 had an MNN tumour, three an MNA tumour and three were MNU.
Group III Skeletal MIBG uptake was evidenced in eight infants, but their Xray films were normal. The sex ratio was 5 males/3 females, and the median age was 5 months (range = 0-11 months). The primary tumour was retroperitoneal in five patients. Two patients presented a single site of uptake on the skeletal MIBG scan, whereas six patients had multiple sites of osteomedullary uptake. No patient had an MNA tumour.
Four patients were treated according to the protocol used for stage 4 disease without HDC and are alive and free of disease in first CR (> 91, 71, 40 and 31 months). The four others received the same treatment administered for stage 4-s disease: one died of progression despite a second-line therapy and three are alive (> 85, 42 and 17 months), two of whom have remained in PR despite combination chemotherapy, radiotherapy and surgery.
Seven of eight infants are therefore alive in CR or PR in this group.
Prognostic factors
The factors likely to influence event-free survival (EFS) were first studied by univariate analysis (logrank test). Factors which were significant or of borderline significance were further analysed by multivariate analysis. The projected overall survival and EFS rates at 5 years are 67.2% (± 6.1%) and 64.1% (± 7.1%) for all 51 infants with stage 4 neuroblastoma. The results of the univariate analysis are given in Table 3 . The comparison of EFS between patients with or without MNA indicated significantly poorer survival in the subgroup with an MNA tumour (P = 0.0004) (Figure 1) . However, the most powerful prognostic indicator was bone lesions (Figure 2 ): indeed EFS was far better in the 30 infants without a bone lesion compared to the 21 with bone lesions (90% (± 5.5%) vs 27.2% (± 10.6%), P < 0.0001). Regarding tumour markers, only the serum ferritin level and VMA/HVA ratio appeared to affect outcome, particularly when ferritin was over twice the normal value (P = 0.008). Conversely, sex, age-atdiagnosis, the site of the primary tumour, as well as histologically proven lymph-node involvement, had no impact on outcome. Multivariate analysis was performed using the Cox regression method with stratification on age, size and the site of the primary tumour, MNA and bone lesions. The only significant prognostic factor was bone lesions (P = 0.001), with a relative risk of 12.06 (95% CI, 2.71-53.5). The EFS rate at 5 years is 11.7% (± 10.6%) for the MNA subgroup with bone lesions and 75% (± 21.7%) for the MNA subgroup without bone lesions. This difference is not statistically significant (P = 0.10) due to the small number of infants.
DISCUSSION
To our knowledge, this is the first multicentre prospective study to focus on infants with metastatic neuroblastoma (NB) with the aim of evaluating both the clinical relevance of MYCN amplification and of bone lesions in such a population. Two groups were defined based on radiological findings, the first comprising infants with bone lesions detected by X-ray (group I) and the second those with no radiologically detected bone lesion (groups II and III). Our patient characteristics were comparable to those of other published studies (Paul et al, 1991; Labreveux de Cervens et al, 1994; Strother et al, 1995; Lampert et al, 1997) . The classic prognostic factors analysed in NB to date were the focus of this study. In terms of age at diagnosis, other authors have already underscored the existence of a more favourable prognosis for disease in younger infants (0-6 months) (De Bernardi et al, 1992; Labreveux de Cervens et al, 1994) . De Bernardi et al (1992) published that infants who were 6-11 months old with stage 4 disease had the worst prognosis. In a smaller series, De Cervens et al (1994) further substantiated this conclusion, but in their study stage 4 patients were not only the oldest but also had bone lesions. Our data confirm that infants with bone lesions are indeed the oldest, as were those with MNA tumours, however age in itself had no impact whatsoever on outcome in the univariate analysis.
With respect to sex as prognostic factor, some investigators have suggested that it has an effect on survival conferring a more favourable outcome on females (Carlsen et al, 1985 ). An excess of male patients in our study did in fact have stage 4 NB and bone lesions but this did not lead to a difference in survival between genders; male and female patients had similar survival rates in the univariate analysis.
The site as a prognostic factor has also been purported to impact on survival. Goon et al (1984) found that neuroblastoma confined to the thorax have the most favourable outcome. In our study, the primary sites were not statistically different between the three groups and had no effect on outcome.
Evidence for the prognostic significance of MYCN oncogene amplification is inconsistent and controversial. MYCN was found to be correlated with a poor prognosis in neuroblastoma (Seeger et al, 1985; Nakagawara et al, 1987; Look et al, 1991; Brodeur et al, 1992) and was demonstrated to be the most relevant adverse prognostic indicator in localized NB . The legitimacy of this finding however has remained open to debate in patients with stage 4 disease > 1 year-of-age. MYCN amplification has also been singled out as conferring a poor prognosis (Bowman et al, 1997; Dubois et al, 1999) year, but this finding was not corroborated by others (Lampert et al, 1997) . Indeed, Lampert et al (1997) reported no difference in the probability of survival between infants with stage 4 NB, with or without a MYCN amplified tumour. In their recent study, Dubois et al (1999) showed that MYCN amplification correlated with increased frequency of bone and intracranial or orbital metastases. In our study, MYCN amplification as a univariate factor correlated significantly with survival (P = 0.0004) (Figure 1 ) and MNA and bone lesions were also significantly correlated (P = 0.001) ( Table 2) . Although certain other biological prognostic indicators, such as serum ferritin and urinary catecholamine excretion (HVA/VMA ratio) appeared to be significant in the univariate analysis, they were finally of marginal importance in the multivariate analysis. This was related to the fact that the VMA/HVA ratio was significantly correlated with bone lesions and MNA, and that there were major variations between serum ferritin determinations between the different centres.
Event-free survival rate at 5 years is 64.1% (± 7.1%) for our entire study population. Paul et al (1991) reported a similar 5-year EFS (75%) for 24 patients and, given the favourable outcome of this series of infants with metastatic NB < 1 year-of-age, did not advocate using HDC in these patients. Strother et al (1995) reported a 5-year actuarial survival rate of 60% for 58 patients. Although survival rates appear comparable, these authors did not analyse the prognostic value of bone lesions, which was the strongest prognostic indicator in the multivariate analysis in our study. Based on our findings, we consider that patients < 1 year with stage 4 NB with bone lesions should be distinguished from patients with the same disease stage and age but no bone lesions, because their outcome is totally different and, as a consequence, the former require more aggressive treatment. Evans et al (1971) already demonstrated that overt bone lesions in infants, which were to be clearly distinguished from bone-marrow involvement without positive radiological findings, virtually always portended a fatal outcome. Since then, the difference between stage 4-s and 4 disease has been clearly established. In addition, MIBG scintigraphy has made it possible to identify a specific group of infants whose X-rays are normal but in whom osteomedullary MIBG uptake is evidenced (group III in this study). Our data suggest that disease in this specific group differs from that of stage 4 NB with radiologically detectable bone lesions because the long-term outcome appears better than that of patients with radiologically detectable bone lesions. Moreover, the prognosis appears to be different from that of stage 4-s disease. In our opinion, the prognosis in group III is similar to that of stage 4-s when bone marrow involvement exceeds the 10% limit stipulated for classification as 4-s by the INSS (Brodeur et al, 1993) . We consider skeletal MIBG uptake to be related to greater bone-marrow involvement, which would account for its role as a prognostic factor. Like stage 4 NB, this stage with MIBG uptake alone requires more aggressive conventional chemotherapy to achieve a complete remission.
With respect to infants affected by a stage 4 unresectable primary tumour (group II), our study confirms the excellent outcome of this stage at this age (< 1 year) (Labreveux de Cervens et al, 1994) . Indeed, only toxicity is incriminated in the 2/22 deaths in group II. The treatment and the prognosis of this stage are the same as that of stage 3 neuroblastoma in patients under 1 yearof-age at diagnosis . According to the three groups, three different treatment regimens were used for this study in which prognostic factors were analysed. Hence, stage 4 neuroblastoma with bone lesions were treated with the most aggressive therapy. Despite the fact that treatment is an important part of outcome, in this series patients with bone lesions had the worst prognosis.
Finally, this study has shown that radiologically detectable bone lesions are a strong prognostic factor conferring a very poor prognosis on infants with bone lesions, especially when their tumours are MNA. Given the poor results of this group, whatever the treatment, new therapeutic approaches need to be investigated in the future.
